Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
Oral Presentation Title: ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: OPTIC Phase 1 Study Update
- Oral Presentation Title: ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: OPTIC Phase 1 Study Update
Adverum intends to issue a press release concurrent with the presentation and to post the data presented on the Publications page in the Pipeline section of the companys website. - Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD.
- The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age.
- ADVM-022, ixoberogene soroparvovec (Ixo-vec), is Adverums clinical-stage gene therapy product candidate being developed for the treatment of wet AMD.